Fresenius Q3/26 adjusted core net income rises 15% to €403 million
Fresenius said Q3/26 adjusted core net income rose 15% to €403 million. Revenue before special items increased 6% to €5.8 billion, and the company raised its FY26 EBIT margin indication to above 11.5%.
1. Quarterly results
Fresenius reported Q3/26 adjusted core EPS of €0.72, up 15% year over year. Revenue before special items climbed 6% to €5.8 billion, while the EBIT margin before special items widened to 11%.
2. Raised margin indication
The group raised its FY26 EBIT margin indication before special items to above 11.5%. It also announced an exclusive development agreement with WuXi Biologics that provides access to up to 37 potential first-to-market biosimilar candidates.
